Entries by Max

ARASAFE Trial Offers Safer Docetaxel-Darolutamide-ADT Regimen for mHSPC

/in , , /by

Recent data presented at the 2025 European Society for Medical Oncology (ESMO) Congress reveal a promising new treatment schedule for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 ARASAFE trial evaluated an alternative docetaxel dosing regimen combined with darolutamide and androgen deprivation therapy (ADT), showing significant reductions in severe toxicities while maintaining effective […]

Phase 1/2 PETRANHA Trial Update: Promising Results Reported at ESMO 2025

/in , , , /by

At the 2025 ESMO Congress, new data from the phase 1/2 PETRANHA trial introduced saruparib (AZD5305), a highly selective PARP1 inhibitor, as a potentially safer and more effective therapeutic partner for androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer. The results highlighted a strong efficacy signal in castration-sensitive disease and ARPI-naïve castration-resistant settings, while […]

Newsletter 42/2025

/in /by

LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hi fellow warriors! New week, new articles. Given my academic and professional background, the most incredible news this week is the first one you’ll find under preclinical research. It hasn’t made much noise, but believe me, it’s something that would have been […]

AI Model Bridges Cellular Biology and Machine Reasoning

/in /by

A collaboration between Yale University and Google DeepMind has led to a rare scientific milestone: an artificial intelligence system that not only analyzed biological data but also generated and experimentally validated a new hypothesis for cancer treatment. Announced on October 15, 2025, the 27‑billion‑parameter foundation model, called Cell2Sentence‑Scale 27B, was developed to interpret single‑cell RNA […]

Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib)

/in /by

Scientists at The Institute of Cancer Research in London have identified a combination therapy that may benefit up to 40 percent of men with advanced prostate cancer, particularly those whose tumors have become resistant to hormone therapies. This approach targets two proteins essential for cancer cell survival: MCL1 and AKT. Direct inhibition of MCL1 has […]

Phase 2: Copper-Based PET Imaging Agent Surpasses Standard Tracer for Early Prostate Cancer Lesion Detection

/in , , /by

The phase 2 Co-PSMA trial conducted at St Vincent’s Hospital in Sydney evaluated 64Cu-SAR-bisPSMA, a novel copper-based PET imaging agent, against the standard 68Ga-PSMA-11 tracer in patients with biochemical recurrence of prostate cancer and low PSA levels. Results showed 64Cu-SAR-bisPSMA detected a statistically greater number of PSMA-positive lesions per patient than the standard agent, particularly […]

Phase 2 Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC

/in , , /by

This Phase II study explores a novel approach to treating metastatic hormone-sensitive prostate cancer (mHSPC) through PSA-triggered intermittent therapy. Traditionally, men with mHSPC are managed with continuous androgen deprivation therapy (ADT) in combination with androgen receptor pathway inhibitors (ARPIs). This strategy has significantly extended survival but often leads to enduring side effects such as fatigue, […]

Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer

/in , /by

A new study published in Nature Signal Transduction and Targeted Therapy reports a major leap in the design of targeted cancer therapies through the development of an in vivo self-assembled nano-PROTAC (proteolysis targeting chimera) system capable of delivering dual-targeted degradation in castration-resistant prostate cancer (CRPC).​ PROTACs have reshaped the drug discovery landscape by inducing selective […]

Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness

/in /by

Researchers have identified two enzymes that serve as critical guardians of prostate cancer cell survival, opening new avenues for enhancing treatment outcomes in one of the most common cancers affecting men worldwide. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that blocking these molecular chaperones can destabilize cancer cells and […]

Phase 3 Trial: Xaluritamig (AMG 509) Plus Abiraterone in mCRPC

/in , , /by

A large international Phase 3 clinical trial  is evaluating a new treatment combination for men with metastatic castration-resistant prostate cancer (mCRPC) who have not yet undergone chemotherapy (in castration resistant settings, prior chemo is allowed). The study is testing xaluritamig (AMG 509) together with abiraterone acetate against the investigator’s choice of standard therapies (docetaxel, cabazitaxel, […]